Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arixtra Clear all
Completed Phase 4 Interventional Results available

Fondaparinux in Critically Ill Patients With Renal Failure

NCT01467583
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Fondaparinux
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Oral Rivaroxaban in Children With Venous Thrombosis

NCT01684423
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

NCT00909064
View directory record Official record
Conditions
Total Knee Replacement
Interventions
Fondaparinux Sodium (Arixtra)
Drug
Lead sponsor
Paul Di Cesare,MD
Other
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

NCT00412464
View directory record Official record
Conditions
Thrombosis, Heparin-induced Thrombocytopenia
Interventions
Fondaparinux
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

NCT01895777
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate, standard of care
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 22, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 3:53 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 3:53 PM EDT
Not listed No phase listed Observational

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

NCT00424281
View directory record Official record
Conditions
ICU Patients 18 Years or Older.
Interventions
Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty

NCT01809054
View directory record Official record
Conditions
Primary Total Hip and Knee Arthroplasty
Interventions
Arixtra, Pneumatic compression stockings, Aspirin
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 22, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional Results available

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683
View directory record Official record
Conditions
Cancer, Thromboembolism
Interventions
Arixtra alone, Arixtra + filter
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 22, 2026, 3:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery

NCT00767559
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
warfarin, Fondaparinux:
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
20 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 22, 2026, 3:53 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

NCT00346879
View directory record Official record
Conditions
Morbid Obesity
Interventions
fondaparinux
Drug
Lead sponsor
Indiana University
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 22, 2026, 3:53 PM EDT
Withdrawn Phase 1 Interventional

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NCT00659399
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Fondaparinux
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

NCT00381888
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
Interventions
fondaparinux sodium
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Early Phase 1 Interventional

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

NCT00894283
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

NCT00413504
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 22, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Results available

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

NCT00673439
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
fondaparinux, warfarin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 22, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 22, 2026, 3:53 PM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 22, 2026, 3:53 PM EDT
Withdrawn Not applicable Interventional

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

NCT00483600
View directory record Official record
Conditions
Kidney Diseases
Interventions
fondaparinux
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 22, 2026, 3:53 PM EDT